Allist(SH:688578)2023-12-01 08:36Group 1: Investor Relations Activities - The company held investor communication meetings on November 29 and 30, 2023, with a total of 13 participants from various financial institutions [2][4]. Group 2: Drug Development and Clinical Trials - Fumetinib shows potential for treating NSCLC with EGFR 20 insertion mutations, with preliminary results from the FAVOUR study indicating an overall response rate (ORR) of 78.6% for the initial treatment group [5]. - The safety profile of Fumetinib is favorable, with most treatment-related adverse events (TRAEs) being grade 1-2, and no patients discontinued treatment due to TRAEs in the initial treatment group [5]. - The company is advancing two registration clinical studies for Fumetinib targeting EGFR 20 insertion mutations, aiming to provide more treatment options for patients [6]. Group 3: International Collaboration and Milestones - The company has partnered with Arrivent to initiate a global Phase III clinical trial for Fumetinib targeting EGFR 20 insertion mutations, with the first patient enrolled overseas [6][7]. - In October 2023, Fumetinib received "Breakthrough Therapy Designation" from the FDA, recognizing its superior efficacy in early clinical studies compared to existing treatments [7]. Group 4: Financial Performance - In Q3 2023, the company reported total revenue of CNY 599 million, a year-on-year increase of 175.67%, and a net profit of CNY 202 million, up 643.57% [10]. - For the first three quarters of 2023, total revenue reached CNY 1.348 billion, reflecting a growth of 160.34%, with a net profit of CNY 410 million, a 661.00% increase [11]. Group 5: Future Pipeline and Strategy - The company emphasizes the development of innovative drugs, with a focus on oncology, including pipelines for KRAS G12D, fourth-generation EGFR-TKIs, and SOS1 inhibitors [12].